Effects of Oral and Transdermal Hormonal Contraception on Vascular Risk Markers
Authors:
- Julia V. JohnsonJJJulia V. Johnson
- Jane LowellJLJane Lowell
- Gary J. BadgerGBGary J. Badger
- Jan RosingJRJan Rosing
- Svetlana TchaikovskiSTSvetlana Tchaikovski
- Mary CushmanMCMary Cushman
- 1 February 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 111 (2) , 278-284
Abstract
To compare the effects of oral and transdermal contraceptives containing similar hormone formulations on vascular risk markers. We conducted a randomized, investigator-blinded, crossover, clinical trial with 24 healthy women, aged 18-35 years, who received 2 months of transdermal or oral contraceptive, 2 months washout, then 2 months of the alternative medication. The transdermal contraceptive contained 0.75 mg ethinyl estradiol and 6 mg norelgestromin. The oral contraceptive contained 35 mcg ethinyl estradiol and 250 mcg norgestimate. Blood samples taken before and after each treatment were analyzed in batch for D-dimer, von Willebrand factor, factor VIII, total and free protein S, antithrombin, fibrinogen, C-reactive protein, and normalized activated protein C sensitivity ratio (nAPCsr) determined with two thrombin generation-based assays, the alpha2macroglobulin-thrombin end point method (alpha2M-IIa) and calibrated automated thrombinography. Repeated measures analysis of variance was used for analysis. For both contraceptives (transdermal, oral) there were significant declines in free (19%, 11%) and total protein S (19%, 13%) and antithrombin (13%, 10%); increases in fibrinogen (8%, 10%), C-reactive protein (220%, 292%), nAPCsr alpha2M-IIa (81%, 61%), and nAPCsr calibrated automated thrombinography (102%, 68%), all P<.05. Transdermal contraceptives had a greater effect than oral contraceptives on free protein S (P=.07), nAPCsr alpha2M-IIa (P=.06), and nAPCsr calibrated automated thrombinography (P=.03). Oral and transdermal contraception with similar hormones had similar adverse effects on vascular risk markers. This suggests that this transdermal contraceptive has at least a similar thrombosis risk as its oral counterpart. ClinicalTrials.gov, www.clinicaltrials.gov, NCT00554632 I.Keywords
This publication has 23 references indexed in Scilit:
- Venous Thromboembolism, Myocardial Infarction, and Stroke Among Transdermal Contraceptive System UsersObstetrics & Gynecology, 2007
- Treatment with combined oral contraceptives induces a rise in serum C‐reactive protein in the absence of a general inflammatory responseJournal of Thrombosis and Haemostasis, 2005
- C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and WomenCirculation, 2005
- Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic reviewThrombosis and Haemostasis, 2005
- Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trialBlood, 2004
- Pharmacokinetics of a contraceptive patch (Evra™/Ortho Evra™) containing norelgestromin and ethinyloestradiol at four application sitesBritish Journal of Clinical Pharmacology, 2002
- Oral Contraceptives and the Risk of Venous ThrombosisNew England Journal of Medicine, 2001
- Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over studyThe Lancet, 1999
- An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostatic variables: Outline of the protocolContraception, 1999
- Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second‐ and third‐generation oral contraceptivesBritish Journal of Haematology, 1997